Bridging Academic Research and Industry
Post Date: May 11, 2026 | Publish Date:
At a recent webinar hosted by Cincinnati Children’s Innovation Ventures, David Lough, PhD, Lead, Academic Partnerships, Chiesi Center of Open Innovation and Competence, also known as The IMPULSE, shared a practical view of how pharmaceutical companies engage with academic research and what it takes to move early discoveries toward real-world impact.
His central point: strong science is essential, but translation depends on how well academia and industry work together.
Where strengths intersect
Academic researchers are uniquely positioned to generate new insights by identifying mechanisms, testing hypotheses, and advancing early discoveries. Industry brings a different set of capabilities: development expertise, regulatory navigation and the ability to scale therapies to reach patients.
That combination is what turns promising ideas into approved treatments. As Lough described, “we have very complementary strengths,” pointing to the critical role partnerships play in bridging discovery and development.
Many widely used therapies reflect this model. Discoveries that begin in academic labs can, with the right partnership, be developed and scaled to reach patients globally.
What industry is looking for
Chiesi’s priorities reflect broader trends across biopharma. Respiratory and neonatal care remain core areas, while rare or ultra-rare diseases have become a major focus for growth. In these areas, expectations are high. New approaches must either be first of their kind or represent a meaningful step change in outcomes.
At the same time, innovation is expanding beyond therapeutics. Digital tools and other non-pharmaceutical solutions are increasingly part of the equation, supporting patients across the entire patient journey including diagnosis, treatment, monitoring and long-term management.
“We’re trying to make earlier bets,” Lough noted, describing a shift toward engaging with promising ideas sooner and helping move them to the next stage. This may include pilot studies as well as sponsored research and collaboration agreements.
How collaboration happens
There is no single pathway for engagement. Industry identifies opportunities through a mix of direct outreach, startup ecosystems and structured innovation programs. Increasingly, companies are engaging earlier, sometimes funding targeted work to help promising ideas reach key development milestones.
Still, not every collaboration moves at the same pace. From Lough’s perspective, the most effective academic partners tend to share a few key traits:
- Openness to collaboration and industry engagement
- Clear, efficient processes around intellectual property
- Willingness to move with speed and flexibility
- Proactive, consistent communication
These factors can be just as important as the underlying science in determining whether a partnership succeeds.
A broader definition of impact
Another shift is the growing emphasis on patient-centered innovation. In rare diseases especially, companies are looking beyond the therapy itself—considering how to shorten diagnostic journeys, improve access and support patients more holistically.
For researchers, the takeaway is clear. Advancing discovery requires more than a strong idea. It requires alignment with real-world pathways including clinical, regulatory and commercial considerations, and often early engagement with partners who can help navigate them. Connecting early with a technology transfer office, like Cincinnati Children’s Innovation Ventures, can help ensure discoveries are protected, positioned and ready for productive collaboration.
Because the ultimate goal is not just to generate knowledge, but to deliver solutions that improve lives.
Don’t Miss a Post:
- Subscribe to the Research Horizons Newsletter
- Follow Cincinnati Children’s Research Foundation on Bluesky, X and LinkedIn
Latest Posts
About this blog
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment. Email researchnews@cchmc.org with questions or ideas.
Subscribe to Our Newsletter